Full text

Turn on search term navigation

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background: Colorectal cancer (CRC) is a highly devastating cancer. Ca2+-dependent channels are now considered key regulators of tumor progression. In this study, we aimed to investigate the association of non-voltage gated Ca2+ channels and Ca2+-dependent potassium channels (KCa) with CRC using the transcriptional profile of their genes. Methods: We selected a total of 35 genes covering KCa channels KCNN14, KCNMA1 and their subunits KCNMB14, endoplasmic reticulum (ER) calcium sensors STIM1 and STIM2, Ca2+ channels ORAI1–3 and the family of cation channels TRP (TRPC1–7, TRPA1, TRPV1/2,4–6 and TRPM1–8). We analyzed their expression in two public CRC datasets from The Cancer Genome Atlas (TCGA) and GSE39582. Results: KCNN4 and TRPM2 were induced while KCNMA1 and TRPM6 were downregulated in tumor tissues comparing to normal tissues. In proximal tumors, STIM2 and KCNN2 were upregulated while ORAI2 and TRPM6 were downregulated. ORAI1 decreased in lymph node metastatic tumors. TRPC1 and ORAI3 predicted poor prognosis in CRC patients. Moreover, we found that ORAI3/ORAI1 ratio is increased in CRC progression and predicted poor prognosis. Conclusions: KCa and Ca2+ channels could be important contributors to CRC initiation and progression. Our results provide new insights on KCa and Ca2+ channels remodeling in CRC.

Details

Title
Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer
Author
Ibrahim, Sajida 1 ; Dakik, Hassan 2 ; Vandier, Christophe 3 ; Chautard, Romain 4   VIAFID ORCID Logo  ; Paintaud, Gilles 5 ; Mazurier, Frédéric 2   VIAFID ORCID Logo  ; Lecomte, Thierry 4 ; Guéguinou, Maxime 1 ; Raoul, William 1   VIAFID ORCID Logo 

 Université de Tours, EA 7501 GICC, 37032 Tours CEDEX 01, France 
 Université de Tours, EA 7501 GICC, 37032 Tours CEDEX 01, France; CNRS ERL 7001 LNOx, 37032 Tours CEDEX 01, France 
 Inserm UMR 1069, Nutrition Croissance et Cancer (N2C), 37032 Tours CEDEX 01, France 
 Université de Tours, EA 7501 GICC, 37032 Tours CEDEX 01, France; CHRU de Tours, Department of Hepato-Gastroenterology and Digestive Oncology, 37044 Tours CEDEX 09, France 
 Université de Tours, EA 7501 GICC, 37032 Tours CEDEX 01, France; CHRU de Tours, Department of Medical Pharmacology, 37044 Tours CEDEX 9, France 
First page
561
Publication year
2019
Publication date
2019
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2547494737
Copyright
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.